FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095696852> ?p ?o ?g. }

• W2095696852 endingPage "S35" @default.
• W2095696852 startingPage "S27" @default.
• W2095696852 abstract "Among the many oncogenic variants of the anaplastic lymphoma kinase (ALK), nucleophosmin 1 (NPM)/ALK fusion protein expressed in the subset of T-cell lymphoma (ALK+TCL) is currently the best characterized. NPM/ALK activates several signal transduction pathways, including PI3K/AKT, MEK/ERK, mTORC1, STAT3, and STAT5b. In turn, the pathways modulate expression and function of many genes and proteins involved in the key cellular functions such as proliferation, growth, survival, metabolism, and angiogenesis. Recent data indicate that NPM/ALK also promotes immune evasion of the ALK+TCL by inducing through STAT3 activation the expression of immunosuppressive cytokines interleukin-10 (IL-10) and transforming growth factor-beta (TGFß) and cell surface protein CD274 (PD-L1, B7-H1). In addition, NPM/ALK protects its own expression by mediating via STAT3 and at least one member of the DNA methyltransferase family DNMT1 epigenetic silencing of the SHP-1 and STAT5a genes. In ALK+TCL cells, SHP-1 and STAT5a proteins act as potent tumor suppressors by promoting degradation of the NPM/ALK protein and inhibiting expression of the NPM/ALK gene, respectively. These findings provide further rationale to therapeutically target ALK and its effector proteins, foremost STAT3. They also suggest that immunotherapeutic approaches to ALK+TCL and, possibly, other ALK-driven malignancies may require inhibition of ALK and STAT3 to achieve the optimal clinical efficacy." @default.
• W2095696852 created "2016-06-24" @default.
• W2095696852 creator A5033598738 @default.
• W2095696852 creator A5052441498 @default.
• W2095696852 creator A5062887811 @default.
• W2095696852 creator A5074922417 @default.
• W2095696852 creator A5078846951 @default.
• W2095696852 creator A5081417229 @default.
• W2095696852 date "2009-04-01" @default.
• W2095696852 modified "2023-10-17" @default.
• W2095696852 title "Anaplastic Lymphoma Kinase (ALK)-Induced Malignancies: Novel Mechanisms of Cell Transformation and Potential Therapeutic Approaches" @default.
• W2095696852 cites W1531048613 @default.
• W2095696852 cites W1534155209 @default.
• W2095696852 cites W1548640328 @default.
• W2095696852 cites W1549526024 @default.
• W2095696852 cites W1943783753 @default.
• W2095696852 cites W1964862727 @default.
• W2095696852 cites W1966474816 @default.
• W2095696852 cites W1968973477 @default.
• W2095696852 cites W1969875569 @default.
• W2095696852 cites W1969889989 @default.
• W2095696852 cites W1977532256 @default.
• W2095696852 cites W1982712429 @default.
• W2095696852 cites W1988689365 @default.
• W2095696852 cites W1993719557 @default.
• W2095696852 cites W1998334213 @default.
• W2095696852 cites W1999468766 @default.
• W2095696852 cites W2000371328 @default.
• W2095696852 cites W2005557370 @default.
• W2095696852 cites W2007739717 @default.
• W2095696852 cites W2008267385 @default.
• W2095696852 cites W2010538519 @default.
• W2095696852 cites W2011504208 @default.
• W2095696852 cites W2011937137 @default.
• W2095696852 cites W2014639631 @default.
• W2095696852 cites W2015376574 @default.
• W2095696852 cites W2017924029 @default.
• W2095696852 cites W2023561138 @default.
• W2095696852 cites W2029169197 @default.
• W2095696852 cites W2034848094 @default.
• W2095696852 cites W2038586807 @default.
• W2095696852 cites W2042386826 @default.
• W2095696852 cites W2047470411 @default.
• W2095696852 cites W2051083170 @default.
• W2095696852 cites W2054989266 @default.
• W2095696852 cites W2055402151 @default.
• W2095696852 cites W2060157525 @default.
• W2095696852 cites W2060275730 @default.
• W2095696852 cites W2061278019 @default.
• W2095696852 cites W2062792867 @default.
• W2095696852 cites W2065338489 @default.
• W2095696852 cites W2070166036 @default.
• W2095696852 cites W2070471476 @default.
• W2095696852 cites W2073851843 @default.
• W2095696852 cites W2080411938 @default.
• W2095696852 cites W2082067798 @default.
• W2095696852 cites W2087852931 @default.
• W2095696852 cites W2090176258 @default.
• W2095696852 cites W2091532311 @default.
• W2095696852 cites W2093507272 @default.
• W2095696852 cites W2093986699 @default.
• W2095696852 cites W2101323887 @default.
• W2095696852 cites W2113382967 @default.
• W2095696852 cites W2114449856 @default.
• W2095696852 cites W2122639773 @default.
• W2095696852 cites W2124478432 @default.
• W2095696852 cites W2124728519 @default.
• W2095696852 cites W2128153005 @default.
• W2095696852 cites W2132047377 @default.
• W2095696852 cites W2136536969 @default.
• W2095696852 cites W2136831156 @default.
• W2095696852 cites W2138590389 @default.
• W2095696852 cites W2140502641 @default.
• W2095696852 cites W2140944026 @default.
• W2095696852 cites W2141410747 @default.
• W2095696852 cites W2147028876 @default.
• W2095696852 cites W2153867442 @default.
• W2095696852 cites W2155464214 @default.
• W2095696852 cites W2162082382 @default.
• W2095696852 cites W2210753338 @default.
• W2095696852 cites W4239762160 @default.
• W2095696852 doi "https://doi.org/10.1053/j.seminoncol.2009.02.007" @default.
• W2095696852 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19393833" @default.
• W2095696852 hasPublicationYear "2009" @default.
• W2095696852 type Work @default.
• W2095696852 sameAs 2095696852 @default.
• W2095696852 citedByCount "40" @default.
• W2095696852 countsByYear W20956968522012 @default.
• W2095696852 countsByYear W20956968522013 @default.
• W2095696852 countsByYear W20956968522014 @default.
• W2095696852 countsByYear W20956968522015 @default.
• W2095696852 countsByYear W20956968522016 @default.
• W2095696852 countsByYear W20956968522017 @default.
• W2095696852 countsByYear W20956968522018 @default.
• W2095696852 countsByYear W20956968522020 @default.
• W2095696852 countsByYear W20956968522021 @default.
• W2095696852 countsByYear W20956968522022 @default.
• W2095696852 crossrefType "journal-article" @default.

• next